SLC22A7 and colorectal carcinoma: Pellicer et al. (European ancestry; Spain) studied the influence of SNPs in the SLC22A7 gene on severe toxicity in 301 patients with CRC (stages I–IV) treated with capecitabine-based regimens and found that the TT genotype of the SLC22A7 rs2270860 SNP (1269C>T; synonymous; p.Ser423Ser) was associated with an increased risk of severe cutaneous toxicity (OR = 17.08; 95% CI = 1.71–170.26; p = 0.016 for TT vs. CT/CC) [25].